Mastering the canonical loop of serine protease inhibitors: Enhancing potency by optimising the internal hydrogen bond network

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Swedberg, Joakim E ^a   de Veer, Simon J ^a   Sit, Kei C ^a   Reboul, Cyril F ^b   Buckle, Ashley M ^b   Harris, Jonathan M ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINE; HYDROGEN; KALLIKREIN; KALLIKREIN 4; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SUNFLOWER TRYPSIN INHIBITOR; TRYPSIN; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL BINDING; COMPUTER MODEL; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; NONHUMAN; ANIMAL; ARMYWORM; BAGG ALBINO MOUSE; CELL LINE; CHEMISTRY; MALE; MOLECULAR DYNAMICS; MOUSE; PATHOLOGY; PROSTATE TUMOR;

HELIANTHUS; MUS;

ANIMALS; CELL LINE; HUMANS; HYDROGEN BONDING; MALE; MICE; MICE, INBRED BALB C; MOLECULAR DYNAMICS SIMULATION; PROSTATIC NEOPLASMS; SERINE PROTEINASE INHIBITORS; SPODOPTERA;

EID: 79955703338     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019302     Document Type: Article

References (51)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591-1597.
3. Sotiropoulou G, Pampalakis G, Diamandis EP, (2009) Functional roles of human kallikrein-related peptidases. J Biol Chem 284: 32989-32994.
4. Swedberg JE, de Veer SJ, Harris JM, (2010) Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia. Biol Chem 391: 357-374.
5. Goettig P, Magdolen V, Brandstetter H, (2010) Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs). Biochimie (In press) DOI:10.1016/j.biochi.2010.06.022.
6. Lawrence MG, Lai J, Clements JA, (2010) Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Endocr Rev 31: 407-446.
7. Xi Z, Klokk TI, Korkmaz K, Kurys P, Elbi C, et al. (2004) Kallikrein 4 is a Predominantly Nuclear Protein and Is Overexpressed in Prostate Cancer. Cancer Res 64: 2365-2370.
8. Veveris-Lowe TL, Lawrence MG, Collard RL, Bui L, Herington AC, et al. (2005) Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr Relat Cancer 12: 631-643.
9. Obiezu CV, Michael IP, Levesque MA, Diamandis EP, (2006) Human kallikrein 4: enzymatic activity, inhibition, and degradation of extracellular matrix proteins. Biol Chem 387: 749-759.
10. Matsumura M, Bhatt AS, Andress D, Clegg N, Takayama TK, et al. (2005) Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries. Prostate 62: 1-13.
11. Beaufort N, Debela M, Creutzburg S, Kellermann J, Bode W, et al. (2006) Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR). Biol Chem 387: 217-222.
12. Mize GJ, Wang W, Takayama TK, (2008) Prostate-specific kallikreins-2 and-4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and-2. Mol Cancer Res 6: 1043-1051.
13. Greenberg DL, Mize GJ, Takayama TK, (2003) Protease-activated receptor mediated RhoA signaling and cytoskeletal reorganization in LNCaP cells. Biochemistry 42: 702-709.
14. Ramsay AJ, Dong Y, Hunt ML, Linn M, Samaratunga H, et al. (2008) Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression. J Biol Chem 283: 12293-12304.
15. Gao J, Collard RL, Bui L, Herington AC, Nicol DL, et al. (2007) Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer. Prostate 67: 348-360.
16. Swedberg JE, Nigon LV, Reid JC, de Veer SJ, Walpole CM, et al. (2009) Substrate-guided design of a potent and selective kallikrein-related peptidase inhibitor for kallikrein 4. Chem Biol 16: 633-643.
17. Luckett S, Garcia RS, Barker JJ, Konarev AV, Shewry PR, et al. (1999) High-resolution structure of a potent, cyclic proteinase inhibitor from sunflower seeds. J Mol Biol 290: 525-533.
18. Legowska A, Debowski D, Lesner A, Wysocka M, Rolka K, (2009) Introduction of non-natural amino acid residues into the substrate-specific P1 position of trypsin inhibitor SFTI-1 yields potent chymotrypsin and cathepsin G inhibitors. Bioorg Med Chem 17: 3302-3307.
19. Long YQ, Lee SL, Lin CY, Enyedy IJ, Wang S, et al. (2001) Synthesis and evaluation of the sunflower derived trypsin inhibitor as a potent inhibitor of the type II transmembrane serine protease, matriptase. Bioorg Med Chem Lett 11: 2515-2519.
20. Costa JR, Yaliraki SN, (2006) Role of rigidity on the activity of proteinase inhibitors and their peptide mimics. J Phys Chem B 110: 18981-18988.
21. Korsinczky ML, Schirra HJ, Rosengren KJ, West J, Condie BA, et al. (2001) Solution structures by 1H NMR of the novel cyclic trypsin inhibitor SFTI-1 from sunflower seeds and an acyclic permutant. J Mol Biol 311: 579-591.
22. Hubbard SJ, Campbell SF, Thornton JM, (1991) Molecular recognition. Conformational analysis of limited proteolytic sites and serine proteinase protein inhibitors. J Mol Biol 220: 507-530.
23. Madala PK, Tyndall JD, Nall T, Fairlie DP, (2010) Update 1 of: Proteases Universally Recognize Beta Strands In Their Active Sites. Chem Rev DOI:10.1021/cr900368a.
24. Marx UC, Korsinczky ML, Schirra HJ, Jones A, Condie B, et al. (2003) Enzymatic cyclization of a potent bowman-birk protease inhibitor, sunflower trypsin inhibitor-1, and solution structure of an acyclic precursor peptide. J Biol Chem 278: 21782-21789.
25. Rawlings ND, Tolle DP, Barrett AJ, (2004) Evolutionary families of peptidase inhibitors. Biochem J 378: 705-716.
26. Laskowski M, Qasim MA, (2000) What can the structures of enzyme-inhibitor complexes tell us about the structures of enzyme substrate complexes? Biochim Biophys Acta 1477: 324-337.
27. Laskowski M Jr, Kato I, (1980) Protein inhibitors of proteinases. Annu Rev Biochem 49: 593-626.
28. Haberkorn U, Eisenhut M, Altmann A, Mier W, (2008) Endoradiotherapy with peptides- status and future development. Curr Med Chem 15: 219-234.
29. Shaw GL, Davis B, Keeler J, Fersht AR, (1995) Backbone dynamics of chymotrypsin inhibitor 2: effect of breaking the active site bond and its implications for the mechanism of inhibition of serine proteases. Biochemistry 34: 2225-2233.
30. Radisky ES, Koshland DE Jr, (2002) A clogged gutter mechanism for protease inhibitors. Proc Natl Acad Sci U S A 99: 10316-10321.
31. Zakharova E, Horvath MP, Goldenberg DP, (2009) Structure of a serine protease poised to resynthesize a peptide bond. Proc Natl Acad Sci U S A 106: 11034-11039.
32. Sousa SF, Fernandes PA, Ramos MJ, (2006) Protein-ligand docking: current status and future challenges. Proteins 65: 15-26.
33. Cozzini P, Kellogg GE, Spyrakis F, Abraham DJ, Costantino G, et al. (2008) Target flexibility: an emerging consideration in drug discovery and design. J Med Chem 51: 6237-6255.
34. Diaz N, Suarez D, (2008) Molecular dynamics simulations of the active matrix metalloproteinase-2: positioning of the N-terminal fragment and binding of a small peptide substrate. Proteins 72: 50-61.
35. Pang YP, Vummenthala A, Mishra RK, Park JG, Wang S, et al. (2009) Potent new small-molecule inhibitor of botulinum neurotoxin serotype A endopeptidase developed by synthesis-based computer-aided molecular design. PLoS One 4: e7730.
36. Anderson JA, Lorenz CD, Travesset A, (2008) General purpose molecular dynamics simulations fully implemented on graphics processing units. J Comput Phys 227: 5342-5359.
37. Harvey M, Giupponi G, De Fabritiis G, (2009) ACEMD: Accelerated molecular dynamics simulations in the microseconds timescale. J Chem Theory Comput 5: 1632.
38. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, et al. (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26: 1781-1802.
39. Guex N, Peitsch MC, (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18: 2714-2723.
40. Krieger E, Koraimann G, Vriend G, (2002) Increasing the precision of comparative models with YASARA NOVA-a self-parameterizing force field. Proteins 47: 393-402.
41. Humphrey W, Dalke A, Schulten K, (1996) VMD: visual molecular dynamics. J Mol Graph 14: 33-38,27-38.
42. Abbenante G, Leung D, Bond T, Fairlie DP, (2000) An efficient Fmoc strategy for the rapid synthesis of peptide para-nitroanilides. Lett Pept Sci 7: 347-351.
43. Morrison JF, Walsh CT, (1988) The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 61: 201-301.
44. Baici A, Gyger-Marazzi M, (1982) The slow, tight-binding inhibition of cathepsin B by leupeptin. A hysteretic effect. Eur J Biochem 129: 33-41.
45. Kennedy AR, (1998) Chemopreventive agents: protease inhibitors. Pharmacol Ther 78: 167-209.
46. Jain S, Hreczuk-Hirst D, Laing P, Gregoriadis G, (2004) Polysialylation: the natural way to improve the stability and pharmacokinetics of protein and peptide drugs. Drug Deliv Systems Sci 4: 3-10.
47. Daly NL, Chen Y-K, Foley FM, Bansal PS, Bharathi R, et al. (2006) The absolute structural requirement for a proline in the P3′-position of Bowman-Birk protease inhibitors is surmounted in the minimized SFTI-1 scaffold. J Biol Chem 281: 23668-23675.
48. Jacobs DJ, Rader AJ, Kuhn LA, Thorpe MF, (2001) Protein flexibility predictions using graph theory. Proteins 44: 150-165.
49. Heinz DW, Hyberts SG, Peng JW, Priestle JP, Wagner G, et al. (1992) Changing the inhibitory specificity and function of the proteinase inhibitor eglin c by site-directed mutagenesis: functional and structural investigation. Biochemistry 31: 8755-8766.
50. Krowarsch D, Cierpicki T, Jelen F, Otlewski J, (2003) Canonical protein inhibitors of serine proteases. Cell Mol Life Sci 60: 2427-2444.
51. Descours A, Moehle D, Renard A, Robinson JA, (2002) A New Family of Beta-Hairpin Mimetics Based on a Trypsin Inhibitor from Sunflower Seeds. ChemBioChem 3: 318-323.